Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ZOTA

ZOTA

Zota Health Care LImited
Micro-capPharma ↗

What the six lenses say about ZOTA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1089.7
2026-09-08
VWAP · 1Y anchor
₹1356
-19.7% from VWAP
P/E · TTM
-47.7×
TTM EPS ₹-22.8
52-week range
9%
position low→high
RSI(14)
42
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How ZOTA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
4.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD413›

The actual numbers

Price vs VWAP (1y)-19.7%
EMA trend stackDown · 21<50<200
Price vs 200-EMA-12.6%
Price vs 50-EMA-8.0%
RSI(14)42
RS vs Nifty 500 · 3M-13.9%
RS vs sector · 3M-20.0%
52-week range9%
Volume vs 30d avg0.60×
Volume vs 60d avg0.70×
ATR(14) · volatility53.3
Bollinger width · vol contraction0.198
FundamentalD539›

The actual numbers

Return on equity (ROE)-10.7%
Operating margin-11.5%
Net margin-13.7%
Revenue growth · YoY+84.1%
Debt / equity0.39×

Full 8-quarter history in the financials table below.

ValuationD10100›

The actual numbers

P/E (TTM)-47.7×
TTM EPS₹-22.8
52-week range9%
CatalystD1064›

The actual numbers

Earnings & momentum46
Capital actions81
Governance116

Every filing in the corporate-announcements panel below.

FlowD550›

The actual numbers

Promoter holding49.4%
Delivery · 30d avg59.7%
Up/down-day asymmetry2.0pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D4 + D5 ) ÷ 2 = 4.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Below threshold
16
Conviction score 16/100 · avg-decile strength 4.5/10
Conviction score16/100›
TechnicalD4›
FundamentalD5›
ValuationD10›
CatalystD10›
FlowD5›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
-3.3pp
+4.7pp
-9.1pp
-12.3pp
-6.3pp
-23.5pp
Nifty 500
Broad-market baseline
-3.3pp
+4.7pp
-10.2pp
-13.9pp
-12.1pp
-28.7pp
Sector
Own-sector index
—
—
-13.0pp
-20.0pp
-25.2pp
-49.5pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ZOTA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1089.70-42.70

Relative strength

RS vs baseline · rebased to 100

ZOTA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
166.44-5.79

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)56677297104129143163
↳ change QoQ—+19.5%+7.2%+34.5%+7.2%+24.0%+10.9%+14.0%
EBITDA (₹cr)-1-0-624609
EBITDA margin-2.2%-0.5%-7.7%2.1%3.9%4.7%—5.5%
PAT (₹cr)-13-12-19-13-14-16-30-14
↳ change QoQ—+4.3%-55.5%+31.4%-7.7%-14.3%-87.5%+53.3%
Net margin-22.6%-18.1%-26.3%-13.4%-13.5%-12.4%-21.0%-8.6%
EPS (₹)-4.80-4.57-6.80-4.50-4.81-5.20-8.73-4.09
D/E————————
YoY growth · Mar '26Revenue +68.0% YoYPAT -7.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 3 Sep '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Sep '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 20 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Monitoring Agency Report
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 Aug '26
    LOWgovernance
    Statement of deviation(s) or variation(s) under Reg. 32
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 6 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Jul '26
    LOWgovernance
    Corrigendum
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Jul '26
    HIGHcapital
    Acquisition
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 1 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 Jun '26
    HIGHcapital
    Acquisition
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma